Elixir Medical to Announce New Clinical Data on Fully Bioresorbable Drug Eluting Coronary Scaffold System and Drug Eluting Stent System at EuroPCR

SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release six-month clinical data for its fully bioresorbable drug-eluting scaffold system, the DESolve™ Bioresorbable Coronary Scaffold, at the EuroPCR Hot Line session in Paris on Wednesday, May 16.